QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases

By /

QurAlis Corporation announced it has closed an oversubscribed $88 million Series B financing, bringing the total funds raised to $143.5 million.

Scroll to Top